Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland

2 septembre 2022 – Swissmedic has temporarily authorised “Spikevax Bivalent Original/Omicron (mRNA-1273.214)” which is the first COVID-19 vaccine containing messenger ribonucleic acid (mRNA) against two coronavirus variants. Trials have shown that a booster dose with this bivalent vaccine produces a stronger immune response than a booster with Spikevax®, the original COVID-19 vaccine from Moderna against the Omicron variants BA.1 und BA.4/5. The side effects profile was similar to the second dose or the booster of the original vaccine, hence no new safety signals were found.

For more information, see here.